SEARCH:   Advanced

Blood, 29 January 2009, Vol. 113, No. 5, pp. 1002-1005. Prepublished online as a Blood First Edition Paper on September 29, 2008; DOI 10.1182/blood-2008-04-152678. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-04-152678v1 113/5/1002    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fehniger, T. A. Articles by Blum, W. Search for Related Content PubMed PubMed Citation Articles by Fehniger, T. A. Articles by Blum, W. Related Collections Free Research Articles Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL TRIALS AND OBSERVATIONS Brief Report Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13 Todd A. Fehniger1, John C. Byrd2,3, Guido Marcucci2,4, Camille N. Abboud1, Cheryl Kefauver2, Jacqueline E. Payton5, Ravi Vij1, and William Blum2 1 Department of Internal Medicine, Division of Oncology, Siteman Cancer Center, Washington University, St Louis, MO; 2 Department of Medicine, Division of Hematology and Oncology, Comprehensive Cancer Center, 3 Division of Medicinal Chemistry, College of Pharmacy, and 4 Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus; and 5 Department of Pathology and Immunology, Siteman Cancer Center, Washington University, St Louis, MO Patients with acute myeloid leukemia (AML) frequently fail chemotherapy due to refractory disease, relapse, or toxicity. Among older AML patients (age > 60 years), there are few long-term survivors. Lenalidomide is a candidate for study in AML based on its clinical activity in a related disorder, myelodysplastic syndrome (MDS), with the 5q– chromosomal abnormality. We report induction of sustained morphologic and cytogenetic complete remission in 2 older AML patients treated with high-dose, single-agent lenalidomide; each patient had trisomy 13 as the sole cytogenetic abnormality. We show for the first time that lenalidomide has clinical activity in this poor-risk cytogenetic subset of AML. The clinical trials described in this paper have been registered with www.clinicaltrials.gov under identifiers NCT00466895 [ClinicalTrials.gov] and NCT00546897 [ClinicalTrials.gov] . CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Le Dieu, D. C. Taussig, A. G. Ramsay, R. Mitter, F. Miraki-Moud, R. Fatah, A. M. Lee, T. A. Lister, and J. G. Gribben Peripheral blood T cells in acute myeloid leukemia (AML) patients at diagnosis have abnormal phenotype and genotype and form defective immune synapses with AML blasts Blood, October 29, 2009; 114(18): 3909 - 3916. [Abstract] [Full Text] [PDF] R. A. Mesa, C. A. Hanson, R. P. Ketterling, S. Schwager, R. A. Knudson, and A. Tefferi Trisomy 13: prevalence and clinicopathologic correlates of another potentially lenalidomide-sensitive cytogenetic abnormality Blood, January 29, 2009; 113(5): 1200 - 1201. [Full Text] [PDF]

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020